These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26458958)

  • 1. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
    Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
    Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer.
    Hara J; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Oncol Rep; 2014 Feb; 31(2):589-96. PubMed ID: 24297447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.
    Hong KO; Kim JH; Hong JS; Yoon HJ; Lee JI; Hong SP; Hong SD
    J Exp Clin Cancer Res; 2009 Feb; 28(1):28. PubMed ID: 19243631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.
    Børretzen A; Gravdal K; Haukaas SA; Mannelqvist M; Beisland C; Akslen LA; Halvorsen OJ
    J Pathol Clin Res; 2021 May; 7(3):253-270. PubMed ID: 33605548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
    Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
    Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
    van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
    Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
    Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
    J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
    Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
    Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy.
    Behnsawy HM; Miyake H; Harada K; Fujisawa M
    BJU Int; 2013 Jan; 111(1):30-7. PubMed ID: 23107154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression.
    Miura N; Yano T; Shoji F; Kawano D; Takenaka T; Ito K; Morodomi Y; Yoshino I; Maehara Y
    Anticancer Res; 2009 Oct; 29(10):4099-106. PubMed ID: 19846957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas.
    Waldmann J; Slater EP; Langer P; Buchholz M; Ramaswamy A; Walz MK; Schmid KW; Feldmann G; Bartsch DK; Fendrich V
    Ann Surg Oncol; 2009 Jul; 16(7):1997-2005. PubMed ID: 19412634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
    Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
    J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
    Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.